Literature DB >> 8568589

Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma.

T Ueki1, T Koji, S Tamiya, P K Nakane, M Tsuneyoshi.   

Abstract

The expression of basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor (FGFR) mRNA was examined in gastric carcinomas by immunohistochemistry and in situ hybridization, respectively. In the 20 advanced carcinomas examined, bFGF was found in 14 (70.0 per cent) and was confined to the tumour cells, whereas FGFR mRNA was demonstrated in 12 (60.0 per cent) and seen in both tumour cells and endothelial cells. The bFGF and FGFR mRNA-positive carcinomas were larger, were more frequently classified as undifferentiated adenocarcinoma, more frequently invaded the serosal layer, and had a higher rate of lymph node metastases than the bFGF and FGFR mRNA-negative carcinomas. Patients with bFGF and FGFR mRNA-positive carcinomas appear to die earlier than those with bFGF and FGFR mRNA-negative tumours. The values for the carcinomas that were positive for either bFGF or FGFR mRNA fell between these two groups. The findings suggest that the autocrine/paracrine bFGF/FGFR channel is associated with undifferentiated gastric carcinomas and may lead to a poorer prognosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8568589     DOI: 10.1002/path.1711770405

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

Review 1.  Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers.

Authors:  Jimmy Hwang
Journal:  J Gastrointest Oncol       Date:  2016-10

2.  Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors.

Authors:  Yuebo Gan; M Guillaume Wientjes; Jessie L-S Au
Journal:  Pharm Res       Date:  2006-06-08       Impact factor: 4.200

Review 3.  Predictive biomarkers in gastric cancer.

Authors:  C Röcken
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-19       Impact factor: 4.322

4.  Expression of basic fibroblast growth factor in intact and ulcerated human gastric mucosa.

Authors:  M A Hull; J L Brough; D G Powe; G I Carter; D Jenkins; C J Hawkey
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 5.  Targeting angiogenesis in pancreatic cancer: rationale and pitfalls.

Authors:  Chery Whipple; Murray Korc
Journal:  Langenbecks Arch Surg       Date:  2008-01-22       Impact factor: 3.445

6.  Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.

Authors:  Y Shou; T Hirano; Y Gong; Y Kato; K Yoshida; T Ohira; N Ikeda; C Konaka; Y Ebihara; F Zhao; H Kato
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

7.  FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort.

Authors:  Thorben Schrumpf; Hans-Michael Behrens; Jochen Haag; Sandra Krüger; Christoph Röcken
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

Review 8.  The dawn of precision medicine in diffuse-type gastric cancer.

Authors:  Akira Ooki; Kensei Yamaguchi
Journal:  Ther Adv Med Oncol       Date:  2022-03-08       Impact factor: 8.168

Review 9.  Angiogenesis-related non-coding RNAs and gastrointestinal cancer.

Authors:  Zahra Sadat Razavi; Kasra Asgarpour; Maryam Mahjoubin-Tehran; Susan Rasouli; Haroon Khan; Mohammad Karim Shahrzad; Michael R Hamblin; Hamed Mirzaei
Journal:  Mol Ther Oncolytics       Date:  2021-05-15       Impact factor: 7.200

10.  Endothelial Rictor is crucial for midgestational development and sustained and extensive FGF2-induced neovascularization in the adult.

Authors:  Fabio Aimi; Stavroula Georgiopoulou; Ina Kalus; Fabienne Lehner; Alica Hegglin; Përparim Limani; Vinicius Gomes de Lima; Markus A Rüegg; Michael N Hall; Nicole Lindenblatt; Elvira Haas; Edouard J Battegay; Rok Humar
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.